Rhythm Pharmaceuticals (RYTM) Gross Profit (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Gross Profit data on file, last reported at $53.0 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 82.25% year-over-year to $53.0 million in Q1 2026; TTM through Mar 2026 was $194.2 million, a 58.3% increase from a year earlier, with the FY2025 full-year figure at $170.3 million, up 45.83% from the prior year.
• Gross Profit for Q1 2026 stood at $53.0 million, up from $52.5 million in the prior quarter.
• Over the last five years, Gross Profit for RYTM reached as high as $53.0 million in Q1 2026 and fell as low as -$9.1 million in Q4 2022.
• Historically, Gross Profit has averaged $24.3 million across 5 years, with a median of $23.2 million in 2024.
• On a YoY basis, Gross Profit climbed as much as 6241.61% in 2022 and fell as far as 674.07% in 2022.
• Year by year, Gross Profit stood at -$9.1 million in 2022, then surged by 331.39% to $21.0 million in 2023, then soared by 81.15% to $38.0 million in 2024, then jumped by 37.87% to $52.5 million in 2025, then grew by 0.96% to $53.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $53.0 million in Q1 2026, $52.5 million in Q4 2025, and $45.8 million in Q3 2025.